A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer

Cancer

Volumn 116, Issue 4, 2010, Pages 814-821

  Moulder, Stacy L ^a   Holmes, Frankie A ^a   Tolcher, Anthony W ^b   Thall, Peter ^a   Broglio, Kristine ^a   Valero, Vicente ^a   Buzdar, Aman U ^a   Arbuck, Susan G ^c   Seidman, Andrew ^d   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy regimen; Infusion schedule; Metastatic breast cancer; Paclitaxel; Toxicity profile

Indexed keywords

DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; INFUSION RATE; MAJOR CLINICAL STUDY; METASTASIS; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MYALGIA; NEUROPATHY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; SURVIVAL RATE;

EID: 76249127140     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24870     Document Type: Article

References (20)

1. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004;22:2061-2068.
2. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996; 14:1858-1867.
3. Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol. 1999;17:3403-3411.
4. Lopes NM, Adams EG, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol. 1993; 32:235-242.
5. Zhan Z, Scala S, Monks A, Hose C, Bates S, Fojo T. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemother Pharmacol. 1997;40:245-250.
6. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994; 12:1621-1629.
7. Seidman AD, Hochhauser D, Gollub M, et al. Ninety-sixhour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol. 1996;14:1877-1884.
8. Jennison C, Turnbull BW. Group Sequential Methods With Applications to Clinical Trials. New York: Chapman & Hall/CRC; 2000.
9. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
11. Cox D. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
12. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
13. Therneau PM Therneau TM. Modeling Survival Data. New York: Springer; 2000.
14. Seidman AD, Hudis CA, Albanell J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol. 1998;16: 3353-3361.
15. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001;19:4216-4223.
16. Sato K, Inoue K, Saito T, et al. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). Jpn J Clin Oncol. 2003;33:371-376.
17. Lombardi D, Crivellari D, Scuderi C, et al. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori. 2004;90:285-288.
18. Gori S, Mosconi AM, Basurtol C, et al. Weekly paclitaxel in metastatic breast cancer patients: a phase II study. Tumori. 2002;88:470-473.
19. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26:1642-169.
20. Verrill MW, Lee J, Cameron DA, et al. Anglo-Celtic IV: first results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly versus 3 weekly Paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). J Clin Oncol. 2007; 25:33s.